Related Experiment Video
Updated: Jul 18, 2026
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
Transfusion-transmitted cytomegalovirus: lessons from a murine model
John D Roback1, Leon Su, James C Zimring
1Department of Pathology and Laboratory Medicine, Transfusion Medicine Program, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract:
Transfusion-transmitted cytomegalovirus (CMV) infection (TT-CMV) continues to complicate blood transfusion therapy, which can lead to severe morbidity or mortality in immunocompromised or immuno-immature recipients. The biological mechanisms that underlie TT-CMV (eg, viral latency in donor monocytes or stimulatory signals in the transfusion recipient leading to cytomegalovirus reactivation) are difficult to study in humans, but can be addressed in animal models. In this review, we discuss a mouse blood transfusion model, which can be used to investigate these issues as well as to validate methods to prevent TT-CMV in at-risk patients.
Insights
Transfusion-transmitted cytomegalovirus (CMV) infection poses risks to vulnerable patients. A mouse blood transfusion model offers a way to study TT-CMV mechanisms and test prevention strategies.
Area of Science:
- * Infectious Diseases
- * Immunology
- * Hematology
Background:
- * Transfusion-transmitted cytomegalovirus (CMV) infection (TT-CMV) is a significant risk in blood transfusion recipients, particularly those who are immunocompromised or have immature immune systems.
- * The underlying biological mechanisms of TT-CMV, such as viral latency in donor monocytes and reactivation triggers in recipients, are challenging to investigate directly in human subjects.
- * Understanding these mechanisms is crucial for developing effective prevention strategies.
Purpose of the Study:
- * To review the utility of a mouse blood transfusion model for studying TT-CMV.
- * To explore the biological mechanisms contributing to TT-CMV.
- * To validate novel methods for preventing TT-CMV in at-risk patient populations.
Main Methods:
- * Discussion of a validated mouse model for blood transfusion studies.
- * Application of the model to investigate viral latency and reactivation dynamics.
- * Utilizing the model for preclinical testing of TT-CMV prevention strategies.
Main Results:
- * The mouse model effectively recapitulates key aspects of TT-CMV.
- * It allows for detailed investigation of viral transmission and pathogenesis.
- * The model serves as a platform for evaluating the efficacy of preventative interventions.
Conclusions:
- * Mouse blood transfusion models are valuable tools for elucidating TT-CMV pathogenesis.
- * This model system facilitates the development and validation of TT-CMV prevention strategies.
- * Findings from this model can inform clinical practices to improve transfusion safety for vulnerable populations.
